The verdict
Our read at a glance.
Whether Lilly's investigational LY3437943/retatrutide can convert strong early obesity, type 2 diabetes, and MASLD signals into durable clinical outcomes with an acceptable tolerability and safety boundary.
- The signal
- Published direct evidence is strongest for phase 1/2 and phase 2a signals: obesity, type 2 diabetes, liver fat/MASLD, eating behavior, lipids, kidney parameters, and body composition. Many Phase 3 and outcomes records are active or completed, but full peer-reviewed Phase 3 and outcomes evidence remains the boundary.
- The unknown
- Whether Phase 3 publications and regulatory review confirm durable benefit-risk, discontinuation and maintenance patterns, lean-mass implications, cardiovascular and renal outcomes, MASLD/MASH outcomes, gallbladder and pancreatitis risk, and tolerability at scale.
- Our read
- High signal, still provisional. Retatrutide belongs on the Watch Closely list because the early signal is unusually strong, but the clinical boundary is still being written by Phase 3 results, outcomes studies, and regulators.
The explainer
Watch the 31:01 explainer.
31K views · May 2026
The mechanism
How it works.
Retatrutide is an investigational peptide drug that activates three metabolic hormone receptors at once: GLP-1, GIP, and glucagon. The GLP-1 and GIP arms act on the brain and pancreas to blunt appetite, slow stomach emptying, and increase glucose-dependent insulin release, while the added glucagon-receptor activity raises energy expenditure and pushes the liver to burn fat. In phase 2 trials this combination drove large body-weight reductions, but the long-term benefit and risk balance has not yet been confirmed in completed phase 3 outcome studies.
Safety & regulatory boundary
The consequential part.
Retatrutide is investigational and not approved by FDA as of 2026-05-16. Lilly's studied product is not interchangeable with compounded, research-use, export-only, non-Lilly, or internet-market products using the same name. GI tolerability and heart-rate signal are direct safety-watch areas.
What's next
What we're watching.
Full Phase 3 publications, regulatory filings, posted registry results, adverse-event patterns, discontinuation and maintenance data, lean-mass analyses, MASLD/MASH data, and cardiovascular, kidney, sleep-apnea, osteoarthritis, and pain outcomes.
Context
Why this is discussed.
Retatrutide sits near the center of obesity-drug attention because early human data suggested large body-weight effects and because TRIUMPH, TRANSCEND, and related outcomes programs are testing broader cardiometabolic, kidney, pain, sleep-apnea, and liver questions.
The evidence base
66 cited references.
Regulatory & labels6
U.S. Food and Drug Administration · Current FDA page
FDA Global Substance Registration System · Current database page
European Medicines Agency · 2024-09-13
Health Canada · Updated 2026-04-09
Therapeutic Goods Administration · 2026-04-13
U.S. Food and Drug Administration · 2026-03-31
Registered trials21
ClinicalTrials.gov · NCT03841630; completed
ClinicalTrials.gov · NCT04143802; completed
ClinicalTrials.gov · NCT04867785; results posted 2023
ClinicalTrials.gov · NCT04881760; results posted 2023
ClinicalTrials.gov · NCT05882045; active not recruiting
ClinicalTrials.gov · NCT05929066; active not recruiting
ClinicalTrials.gov · NCT05929079; active not recruiting
ClinicalTrials.gov · NCT05931367; completed
ClinicalTrials.gov · NCT05936151; completed
ClinicalTrials.gov · NCT06383390; active not recruiting
ClinicalTrials.gov · NCT06260722; active not recruiting
ClinicalTrials.gov · NCT06297603; active not recruiting
ClinicalTrials.gov · NCT06354660; completed
ClinicalTrials.gov · NCT06662383; active not recruiting
ClinicalTrials.gov · NCT06859268; active not recruiting
ClinicalTrials.gov · NCT06982846; active not recruiting
ClinicalTrials.gov · NCT06982859; recruiting
ClinicalTrials.gov · NCT07035093; recruiting
ClinicalTrials.gov · NCT07165028; recruiting
ClinicalTrials.gov · 2026 listing
ClinicalTrials.gov · NCT07357415; recruiting
Indexed literature (PubMed)34
Coskun et al. · 2022
Urva et al. · 2022
Rosenstock et al. · 2023
Jastreboff et al. · 2023
Sanyal et al. · 2024
Urva et al. · 2023
Coskun et al. · 2025
Heerspink et al. · 2025
Kanu et al. · 2025
Kanu et al. · 2025
Wen et al. · 2025
Pearson et al. · 2026
Study authors · 2025
Giblin et al. · 2026
Heerspink et al. · 2025
Panou et al. · 2026
Abouelmagd et al. · 2025
Tewari et al. · 2025
Pasqualotto et al. · 2024
Ayesh et al. · 2024
Misra et al. · 2025
Tetelbaun et al. · 2024
Li et al. · 2024
Briand et al. · 2026
Viebahn et al. · 2025
Neumann et al. · 2026
Neumann et al. · 2025
Goldney et al. · 2025
Son et al. · 2026
Alavi et al. · 2026
Cho and Jung · 2026
Sinha and Ghosal · 2025
Wang et al. · 2025
Rodriguez and Hartmann · 2025
Sponsor & other sources5
World Health Organization · 2022
Eli Lilly and Company · Current sponsor page
Eli Lilly and Company · 2026-03-19
Eli Lilly and Company · 2025-12-11
Eli Lilly and Company · 2026-04-30
Keep reading